MicroRNA and Other Non-Coding RNAs in Epstein–Barr Virus-Associated Cancers

Notarte, Kin Israel; Senanayake, Suranga L; Macaranas, Imee; Albano, Pia Marie; Mundo, Lucia; Fennell, Éanna; Leoncini, Lorenzo; Murray, Paul G.

doi:10.3390/cancers13153909

Cited by 22 publications

(12 citation statements)

References 245 publications

(306 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cellular lncRNAs can be differentially induced by EBV infection. The dysregulated lncRNAs probably modulate tumorigenesis and other biological functions (28)(29)(30). Our result is consistent with others' reports that SNHG8 is associated with the progression in multiple types of cancer in the liver, colon, lung, ovary, prostate, esophagus, and so on (15,(31)(32)(33)(34)(35).…”

Section: Discussionsupporting

confidence: 92%

SNHG8 Promotes the Progression of Epstein–Barr Virus-Associated Gastric Cancer via Sponging miR-512-5p and Targeting TRIM28

Zou

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

SNHG8, a family member of small nucleolar RNA host genes (SNHG), has been reported to act as an oncogene in gastric carcinoma (GC). However, its biological function in Epstein–Barr virus (EBV)-associated gastric cancer (EBVaGC) remains unclear. This study investigated the role of SNHG8 in EBVaGC. Sixty-one cases of EBVaGC, 20 cases of non-EBV-infected gastric cancer (EBVnGC), and relative cell lines were studied for the expression of SNHG8 and BHRF1 (BCL2 homolog reading frame 1) encoded by EBV with Western blot and qRT-PCR assays. The relationship between the expression levels of SNHG8 and the clinical outcome in 61 EBVaGC cases was analyzed. Effects of overexpression or knockdown of BHRF1, SNHG8, or TRIM28 on cell proliferation, migration, invasion, and cell cycle and the related molecules were determined by several assays, including cell proliferation, colony assay, wound healing assay, transwell invasion assay, cell circle with flow cytometry, qRT-PCR, and Western blot for expression levels. The interactions among SNHG8, miR-512-5p, and TRIM28 were determined with Luciferase reporter assay, RNA immunoprecipitation (RIP), pull-down assays, and Western blot assay. The in vivo activity of SNHG8 was assessed with SNHG8 knockdown tumor xenografts in zebrafish. Results demonstrated that the following. (1) BHRF1 and SNHG8 were overexpressed in EBV-encoded RNA 1-positive EBVaGC tissues and cell lines. BHRF1 upregulated the expressions of SNHG8 and TRIM28 in AGS. (2) SNHG8 overexpression had a significant correlation with tumor size and vascular tumor thrombus. Patients with high SNHG8 expression had poorer overall survival (OS) compared to those with low SNHG8 expression. (3) SNHG8 overexpression promoted EBVaGC cell proliferation, migration, and invasion in vitro and in vivo, cell cycle arrested at the G2/M phase via the activation of BCL-2, CCND1, PCNA, PARP1, CDH1, CDH2 VIM, and Snail. (4) Results of dual-luciferase reporter assay, RNA immunoprecipitation, and pull-down assays indicated that SNHG8 sponged miR-512-5p, which targeted on TRIM28 and promoted cancer malignant behaviors of EBVaGC cells. Our data suggest that BHRF1 triggered the expression of SNHG8, which sponged miR-512-5p and upregulated TRIM28 and a set of effectors (such as BCL-2, CCND1, CDH1, CDH2 Snail, and VIM) to promote EBVaGC tumorigenesis and invasion. SNHG8 could be an independent prognostic factor for EBVaGC and sever as target for EBVaGC therapy.

show abstract

Section: Discussionsupporting

confidence: 92%

SNHG8 Promotes the Progression of Epstein–Barr Virus-Associated Gastric Cancer via Sponging miR-512-5p and Targeting TRIM28

Zou

Liu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In recent years, various mirs have been confirmed to exhibit prognostic value in a variety of human cancers, and a great many of mirs have also been proved acting as a co-effector with other elements in tumor progression such as: cellular proliferation, survival, migration, and immune evasion. Thus, the mirs play an important role in the field of malignant tumor ( 10 ). The study by Zhao et al ( 44 ), showed that mir-375 not only reduced the stemness, but also decreased adriamycin resistance of breast cancer cells, indicating that mir-375 may inhibit the stemness breast cancer cells by targeting JAK2.…”

Section: Discussionmentioning

confidence: 99%

“…Non-coding RNA plays a vital role in cancer biology and provides potential targets for cancer intervention ( 8 , 9 ). Early studies had indicated that non-coding RNA had the potential clinical utility for diagnosing and prognosticating cancers ( 10 ). One type of non-coding RNA is called micro-RNA (mir), which ranges in size from 20-24 nucleotides ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of micro-RNA 375, 133, 143, 145 in esophageal carcinoma: A systematic review and meta-analysis

Fang

Zhou

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Many studies have confirmed that micro-RNA (mir) is related to the prognosis of esophageal carcinoma (EC), suggesting the mir could be used to guide the therapeutic strategy of EC. Some of mir molecules are considered as favorable prognostic factors for EC. The purpose of our study is to evaluate the prognostic potential of mir-375, 133, 143, 145 in primary EC, we summarized all the results from available studies, aiming delineating the prognostic role of mir in EC. Relevant studies were identified by searching databases including Medline, Embase, Web of science, Cochrane Library. The studies which explored the prognostic value of mir-375, 133, 143, 145 expressions on survival outcomes in patients with EC were included in this study. The hazard ratios (HR) and their responding 95% confidence interval (CI) were also extracted. A total of 25 studies were collected, including 1260 patients, and the prognostic values of four mirs in EC were analyzed. Survival outcomes including overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) were used as the primary endpoint to evaluate the prognostic value of mir. The pooled analysis results showed that up-regulation of mir-375 indicated favorable OS (HR=0.50; 95%CI: 0.37-0.69; P<0.001). In addition, the up-regulation of mir-133 (HR=0.40, 95%CI: 0.24-0.65, P<0.001), 143 (HR=0.40, 95%CI: 0.21-0.76, P < 0.001) and 145 (HR=0.55, 95%CI: 0.34-0.90, P<0.001) are also proved as protected factors in EC. Therefore, our study demonstrated that these mirs may have the potential to be used as prognostic biomarkers for EC in clinical practice.

show abstract

“…EBV miRNAs’ diagnostic value as clinical biomarkers for the detection for the EBV-associated development of various tumours has not yet been clinically applied. The main challenges for the use of EBV miRNAs in the clinical setting revolves around identifying unique or common v-miRNAs that can be used as specific biomarkers for various cancers [ 216 ]. Such challenges require large-scale clinical studies to elucidate and verify their translation and application in clinical settings.…”

Section: Challenges and Opportunities Of V-mirnas Use In Theranostics...mentioning

confidence: 99%

Viral Encoded miRNAs in Tumorigenesis: Theranostic Opportunities in Precision Oncology

et al. 2022

View full text Add to dashboard Cite

About 15% of all human cancers have a viral etiology. Although progress has been made, understanding the viral oncogenesis and associated molecular mechanisms remain complex. The discovery of cellular miRNAs has led to major breakthroughs. Interestingly, viruses have also been discovered to encode their own miRNAs. These viral, small, non-coding miRNAs are also known as viral-miRNAs (v-miRNAs). Although the function of v-miRNAs largely remains to be elucidated, their role in tumorigenesis cannot be ignored. V-miRNAs have also been shown to exploit the cellular machinery to benefit viral replication and survival. Although the discovery of Hepatitis C virus (HCV), and its viral miRNAs, is a work in progress, the existence of HPV-, EBV-, HBV-, MCPyV- and KSHV-encoded miRNA has been documented. V-miRNAs have been shown to target host factors to advance tumorigenesis, evade and suppress the immune system, and deregulate both the cell cycle and the apoptotic machinery. Although the exact mechanisms of v-miRNAs-induced tumorigenesis are still unclear, v-miRNAs are active role-players in tumorigenesis, viral latency and cell transformation. Furthermore, v-miRNAs can function as posttranscriptional gene regulators of both viral and host genes. Thus, it has been proposed that v-miRNAs may serve as diagnostic biomarkers and therapeutic targets for cancers with a viral etiology. Although significant challenges exist in their clinical application, emerging reports demonstrate their potent role in precision medicine. This review will focus on the roles of HPV-, HCV-, EBV-, HBV-, MCPyV-, and KSHV-produced v-miRNAs in tumorigenesis, as effectors in immune evasion, as diagnostic biomarkers and as novel anti-cancer therapeutic targets. Finally, it will discuss the challenges and opportunities associated with v-miRNAs theranostics in precision oncology.

show abstract

MicroRNA and Other Non-Coding RNAs in Epstein–Barr Virus-Associated Cancers

Cited by 22 publications

References 245 publications

SNHG8 Promotes the Progression of Epstein–Barr Virus-Associated Gastric Cancer via Sponging miR-512-5p and Targeting TRIM28

SNHG8 Promotes the Progression of Epstein–Barr Virus-Associated Gastric Cancer via Sponging miR-512-5p and Targeting TRIM28

Prognostic value of micro-RNA 375, 133, 143, 145 in esophageal carcinoma: A systematic review and meta-analysis

Viral Encoded miRNAs in Tumorigenesis: Theranostic Opportunities in Precision Oncology

Contact Info

Product

Resources

About